An external collaboration platform in R&D, education, technology, and government affairs; iDREAM is an initiative being implemented through local bio-hubs and launched in 2018 in our Emerging Markets. These bio-hubs improve local capacity for R&D to address local needs. In 2018, AstraZeneca launched iDREAM hubs in Russia, Brazil and Taiwan with important collaboration agreements signed:

  • In July 2018 - We signed a Memorandum of Understanding (MOU)  in Russia with the Skolkovo Institute of Science and Technology (Skoltech), which is focused on education of highly-skilled professionals for the pharmaceutical industry as well as joint research activities. Previously, in collaboration with Skolkovo Foundation, we had launched an ‘Accelerator’ programme focused on supporting scientists to develop treatments and diagnosis systems for our main therapy areas. Now this programme is included in the scope of our iDREAM collaboration. 

  • In August 2018 - We signed an MOU with the Brazilian Israeli Beneficent Society Albert Einstein to launch the iDREAM hub in Brazil. The ​​collaboration programme focuses on cardiovascular, renal and metabolic diseases, and includes initiatives to foster early and late stage clinical development, support innovation through startups acceleration and also implement education programmes.

  • In September 2018 - We signed a Letter of Intent with the Taiwan BioHub, the newly established flagship biopharmaceutical innovation hub of the Taiwanese government, which laid the groundwork for the Taiwan iDREAM hub. Our partner is at the centre of Taiwan’s biomedical ecosystem and gives us access to the national academy of science and other leading biomedical research institutions. Upcoming collaborations will likely cover digital health, entrepreneurship and advanced R&D topics such as proteo-genomics and cardiac drug delivery targets.

Building the Healthcare Innovation of the Future

Following all of our fantastic efforts to bring innovation to patients at a country level, as part of the next phase in our iDREAM journey we wanted to connect up this culture across the whole region. On the 3-4 December 2018 at the University of Cambridge, our cross-functional AstraZeneca International Science Board (AZiSB) team launched the inaugural International Future Healthcare Forum, bringing together our iDREAM hubs from Russia, Brazil and Taiwan, as well as potential hubs from Australia, Turkey and China, to share and collaborate on the latest developments in life sciences innovation.

This annual, best-in-class forum showcased our iDREAM initiative and demonstrated the value of an integrated science ecosystem, connecting education, R&D and government affairs across our International region. It also allowed our hubs, as well as potential hubs, to pursue opportunities with potential partners to drive the next wave of biomedical innovation.

Attending and presenting at the inaugural International Future Healthcare Forum were delegates from the UK ‘Cambridge Cluster’ (Europe’s largest technology cluster), delegates from Russia including representatives from the Skolkovo Foundation, Skoltech and start-up companies in the innovation industry, delegates from Brazil including representatives from the Albert Einstein Institute and start-up companies in the innovation industry, delegates from Taiwan from institutions including Academia Sinica, BioHub Taiwan, National Biotechnology Research Park, National Taiwan University/Taipei Medical University plus government officials, as well as key delegates from Australia, China and Turkey.

In addition, AstraZeneca representatives from across the International region, IMED, MedImmune, GMA, GMD, Business Development, Corporate Affairs, IT and our BioVenture Hub in Sweden attended with many showcasing their insights on the future of healthcare innovation and how this iDREAM initiative can lead a growth through innovation philosophy into 2019.